| Chemical Properties | White to Off-White Crystalline Powder |
| Uses | An α-1-adrenergicblocker related to prazosin. |
| Uses | Terazosin is used for the same indications as is prazosin; however, it has the advantage of
being able to be used once a day. |
| Uses | An a-1-adrenergicblocker related to prazosin |
| Definition | ChEBI: Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist. |
| Clinical Use | Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH) |
| Synthesis | Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-
piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a
tetrahydrofuryl radical. It is synthesized in exactly the same manner except using
1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51]. |
| Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination. |
| Metabolism | Terazosin is metabolised in the liver; one of the
metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the
urine, as unchanged drug and metabolites. |
